JP2024520832A5 - - Google Patents

Info

Publication number
JP2024520832A5
JP2024520832A5 JP2023576035A JP2023576035A JP2024520832A5 JP 2024520832 A5 JP2024520832 A5 JP 2024520832A5 JP 2023576035 A JP2023576035 A JP 2023576035A JP 2023576035 A JP2023576035 A JP 2023576035A JP 2024520832 A5 JP2024520832 A5 JP 2024520832A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032715 external-priority patent/WO2022261240A2/en
Publication of JP2024520832A publication Critical patent/JP2024520832A/ja
Publication of JP2024520832A5 publication Critical patent/JP2024520832A5/ja
Pending legal-status Critical Current

Links

JP2023576035A 2021-06-08 2022-06-08 セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 Pending JP2024520832A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163208391P 2021-06-08 2021-06-08
US63/208,391 2021-06-08
US202163241662P 2021-09-08 2021-09-08
US63/241,662 2021-09-08
PCT/US2022/032715 WO2022261240A2 (en) 2021-06-08 2022-06-08 Dimethoxyphenylalkylamine activators of serotonin receptors

Publications (2)

Publication Number Publication Date
JP2024520832A JP2024520832A (ja) 2024-05-24
JP2024520832A5 true JP2024520832A5 (https=) 2025-06-17

Family

ID=84426423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576035A Pending JP2024520832A (ja) 2021-06-08 2022-06-08 セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤

Country Status (11)

Country Link
US (3) US11926574B2 (https=)
EP (1) EP4351548A4 (https=)
JP (1) JP2024520832A (https=)
KR (1) KR20240019157A (https=)
AU (1) AU2022288926A1 (https=)
BR (1) BR112023025599A2 (https=)
CA (1) CA3216096A1 (https=)
CL (1) CL2023003662A1 (https=)
IL (1) IL309074A (https=)
MX (1) MX2023014630A (https=)
WO (1) WO2022261240A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
EP4608806A1 (en) * 2022-10-28 2025-09-03 Cybin IRL Limited Phenethylamine compounds, compositions, and methods of use
WO2024124056A1 (en) * 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637735A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4637736A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045180B2 (ja) 1977-05-17 1985-10-08 第一製薬株式会社 2−アミノテトラリン誘導体
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
BRPI0713736A2 (pt) 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US20080318957A1 (en) 2007-05-11 2008-12-25 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2011047165A1 (en) 2009-10-16 2011-04-21 Southern Illinois University Edwardsville Methods for treating memory impairment
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
GB201409516D0 (en) * 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US10454900B2 (en) 2015-09-25 2019-10-22 Mcafee, Llc Remote authentication and passwordless password reset
CN110177581B (zh) 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
WO2019084338A1 (en) 2017-10-25 2019-05-02 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
EP4417596B1 (en) 2017-11-06 2026-04-29 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a-beta-42 oligomer formation
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
AU2019324952B2 (en) * 2018-08-22 2024-10-24 University Of Technology Sydney NBOMe test
JP7731868B2 (ja) 2019-08-02 2025-09-01 エースロット,インコーポレイテッド TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US12534425B2 (en) 2020-06-29 2026-01-27 Gilgamesh Pharmaceuticals, Inc. Phenalkylamines and methods of treating mood disorders
CN119285527A (zh) 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
JP2024512796A (ja) 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク. サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
EP4337220A4 (en) 2021-05-11 2025-07-02 Saint Josephs Univ SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
CA3239571A1 (en) 2021-12-15 2023-06-22 Noel Aaron Powell Fused pyrrolidine psychoplastogens and uses thereof
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
WO2024124056A1 (en) 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637736A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
EP4637735A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4680236A2 (en) 2023-03-16 2026-01-21 ATAI Therapeutics, Inc. 3-alkylamine indole activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Similar Documents

Publication Publication Date Title
JP2024520832A5 (https=)
JP2005523922A5 (https=)
JP2023502441A5 (https=)
JP2024520481A5 (https=)
JP2020169171A5 (https=)
JP2024522174A5 (https=)
JP2006515339A5 (https=)
JP2009535307A5 (https=)
JP2010530881A5 (https=)
JP2018524339A5 (https=)
JP2003521537A5 (https=)
JP2012505871A5 (https=)
JP2019518046A5 (https=)
JP2023511349A5 (https=)
JP2024545787A5 (https=)
JP2024541910A5 (https=)
JP2009523841A5 (https=)
JP2007516205A5 (https=)
JP2020063289A5 (https=)
JP2010501478A5 (https=)
JP2011526247A5 (https=)
JPWO2023106310A5 (https=)
JP2024521895A5 (https=)
JP2024542969A5 (https=)
JP2020111571A5 (https=)